Literature DB >> 21938451

Errors noted in: re: Migliore A, Bizzi E, Broccoli S Laganà (2011). Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Published on line June 21st 2011.

Christopher O'Regan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21938451     DOI： 10.1007/s10067-011-1850-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  7 in total

1.  Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

Authors:  Christian E Antoni; Arthur Kavanaugh; Bruce Kirkham; Zuhre Tutuncu; Gerd R Burmester; Udo Schneider; Daniel E Furst; Jerry Molitor; Edward Keystone; Dafna Gladman; Bernhard Manger; Siegfried Wassenberg; Ralf Weier; Daniel J Wallace; Michael H Weisman; Joachim R Kalden; Josef Smolen
Journal:  Arthritis Rheum       Date:  2005-04

2.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Philip J Mease; Dafna D Gladman; Christopher T Ritchlin; Eric M Ruderman; Serge D Steinfeld; Ernest H S Choy; John T Sharp; Peter A Ory; Renee J Perdok; Mark A Weinberg
Journal:  Arthritis Rheum       Date:  2005-10

3.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

Authors:  P J Mease; B S Goffe; J Metz; A VanderStoep; B Finck; D J Burge
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

4.  Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Authors:  C Antoni; G G Krueger; K de Vlam; C Birbara; A Beutler; C Guzzo; B Zhou; L T Dooley; A Kavanaugh
Journal:  Ann Rheum Dis       Date:  2005-01-27       Impact factor: 19.103

5.  Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.

Authors:  Philip J Mease; Alan J Kivitz; Francis X Burch; Evan L Siegel; Stanley B Cohen; Peter Ory; David Salonen; Joel Rubenstein; John T Sharp; Wayne Tsuji
Journal:  Arthritis Rheum       Date:  2004-07

6.  Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.

Authors:  Mark C Genovese; Philip J Mease; Glen T D Thomson; Alan J Kivitz; Renee J Perdok; Mark A Weinberg; John Medich; Eric H Sasso
Journal:  J Rheumatol       Date:  2007-04-15       Impact factor: 4.666

Review 7.  Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Authors:  M Rodgers; D Epstein; L Bojke; H Yang; D Craig; T Fonseca; L Myers; I Bruce; R Chalmers; S Bujkiewicz; M Lai; N Cooper; K Abrams; D Spiegelhalter; A Sutton; M Sculpher; N Woolacott
Journal:  Health Technol Assess       Date:  2011-02       Impact factor: 4.014
  7 in total
  1 in total

1.  Use of biologic agents in ocular manifestations of rheumatic disease.

Authors:  Courtney L Kraus; Susan M Culican
Journal:  Int J Rheumatol       Date:  2011-12-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.